NeuGene® Clinical Development Overview

Initial applications for NeuGene antisense compounds include use in drug metabolism and in treating cardiovascular disease, cancer, polycystic kidney disease, and viral diseases. AVI currently has NeuGene compounds at various stages of clinical development as summarized in the table below.

NeuGene Antisense Clinical Development Program
Preclinical Phase I/Ib Phase II Phase III
Resten-NG
for Restenosis		 Completed Completed Completed Planned
Resten-MP
IV for Restenosis		 Completed Completed Completed  
AVI-4065
for Hepatitis C		 Completed Completed    
AVI-6001
for Influenza/Avian Flu		 In Progress      
AVI-6002
for Ebola Zaire virus		 In Progress Planned    
AVI-6003
for Marburg Musoke virus		 In Progress Planned    
AVI-4557
for Drug Metabolism		  Completed Completed    
AVI-4658
for Muscular Dystrophy		  Completed In Progress    
AVI-3378
for Rheumatoid Arthritis		 In Progress      

CompletedCompleted In ProgressIn Progress In ProgressPlanned

During the past three years, AVI has completed eleven clinical trials using NeuGene antisense compounds. Conclusions from these studies are summarized below:

  • No drug-related adverse events found after treating more than 250 patients
  • Multiple delivery strategies evaluated: intravenous (IV), subcutaneous, intracoronary (IC) catheter, oral
  • Phase II primary endpoints met in both cardiovascular restenosis and drug metabolism